Alexion Pharmaceuticals Inc. (ALXN) Financials Nov
Post# of 250665
Posted On: 11/18/2014 9:35:54 PM
Alexion Pharmaceuticals Inc. (ALXN) Financials Nov 18, 2014, 6:50 p.m.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for Alexion Pharmaceuticals Inc.
Fiscal year is January-December. All values USD millions. 2009 2010 2011 2012 2013 5-year trend
Sales/Revenue 383.44M 532.18M 789.99M 1.12B 1.51B
Cost of Goods Sold (COGS) incl. D&A 57.53M 80.23M 110.76M 150.1M 195.72M
COGS excluding D&A 45.06M 64.44M 93.14M 126.21M 168.38M
Depreciation & Amortization Expense 12.47M 15.79M 17.62M 23.89M 27.34M
Depreciation 7.57M 11M 12.24M 15.19M 19.09M
Amortization of Intangibles 4.91M 4.79M 5.38M 8.7M 8.26M
Gross Income 325.91M 451.95M 679.23M 971.14M 1.32B
2009 2010 2011 2012 2013 5-year trend
SG&A Expense 242.21M 310.09M 428.36M 583.94M 779.89M
Research & Development 78.1M 92.84M 131.51M 215.58M 306.96M
Other SG&A 164.11M 217.25M 296.85M 368.36M 472.93M
Other Operating Expense 0 0 0 0 0
Unusual Expense 7.22M (9.44M) 12.7M (7.78M) 39.43M
EBIT after Unusual Expense (7.22M) 9.44M (12.7M) 7.78M (39.43M)
Non Operating Income/Expense 6.65M (3.1M) (9.63M) 8.14M 30.03M
Non-Operating Interest Income 786,000 1.51M 1.91M 1.84M 3.43M
Equity in Affiliates (Pretax) 0 0 0 0 0
Interest Expense 606,000 704,000 788,000 7.4M 4.11M
Gross Interest Expense 4.03M 704,000 788,000 7.4M 4.11M
Interest Capitalized 3.43M - - - -
Pretax Income 83.31M 149.01M 229.67M 397.57M 526.27M
Income Tax (211.85M) 51.98M 54.35M 142.74M 273.37M
Income Tax - Current Domestic (7.74M) 5.01M (904,000) (2.09M) 141.05M
Income Tax - Current Foreign 4.6M 9.73M 13.19M 73.29M 34.98M
Income Tax - Deferred Domestic (207.6M) 40.57M 45.46M 114.81M 92.04M
Income Tax - Deferred Foreign (1.11M) (3.33M) (3.4M) (43.26M) 5.31M
Income Tax Credits 0 0 0 - 0
Equity in Affiliates 0 0 0 0 0
Other After Tax Income (Expense) 0 0 0 0 0
Consolidated Net Income 295.17M 97.03M 175.32M 254.82M 252.9M
Minority Interest Expense 0 0 0 0 0
Net Income 295.17M 97.03M 175.32M 254.82M 252.9M
Extraordinaries & Discontinued Operations 0 0 0 0 0
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg 0 0 0 0 0
Discontinued Operations 0 0 0 0 0
Net Income After Extraordinaries 295.17M 97.03M 175.32M 254.82M 252.9M
Preferred Dividends 0 0 0 0 0
Net Income Available to Common 295.17M 97.03M 175.32M 254.82M 252.9M
EPS (Basic) 1.73 0.55 0.96 1.34 1.29
Basic Shares Outstanding 170.65M 178.54M 183.22M 190.46M 195.53M
EPS (Diluted) 1.63 0.52 0.91 1.28 1.27
Diluted Shares Outstanding 181.16M 186.07M 191.81M 198.5M 199.71M
EBITDA 96.17M 157.65M 268.49M 411.09M 563.69M
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for Alexion Pharmaceuticals Inc.
Fiscal year is January-December. All values USD millions. 2009 2010 2011 2012 2013 5-year trend
Sales/Revenue 383.44M 532.18M 789.99M 1.12B 1.51B
Cost of Goods Sold (COGS) incl. D&A 57.53M 80.23M 110.76M 150.1M 195.72M
COGS excluding D&A 45.06M 64.44M 93.14M 126.21M 168.38M
Depreciation & Amortization Expense 12.47M 15.79M 17.62M 23.89M 27.34M
Depreciation 7.57M 11M 12.24M 15.19M 19.09M
Amortization of Intangibles 4.91M 4.79M 5.38M 8.7M 8.26M
Gross Income 325.91M 451.95M 679.23M 971.14M 1.32B
2009 2010 2011 2012 2013 5-year trend
SG&A Expense 242.21M 310.09M 428.36M 583.94M 779.89M
Research & Development 78.1M 92.84M 131.51M 215.58M 306.96M
Other SG&A 164.11M 217.25M 296.85M 368.36M 472.93M
Other Operating Expense 0 0 0 0 0
Unusual Expense 7.22M (9.44M) 12.7M (7.78M) 39.43M
EBIT after Unusual Expense (7.22M) 9.44M (12.7M) 7.78M (39.43M)
Non Operating Income/Expense 6.65M (3.1M) (9.63M) 8.14M 30.03M
Non-Operating Interest Income 786,000 1.51M 1.91M 1.84M 3.43M
Equity in Affiliates (Pretax) 0 0 0 0 0
Interest Expense 606,000 704,000 788,000 7.4M 4.11M
Gross Interest Expense 4.03M 704,000 788,000 7.4M 4.11M
Interest Capitalized 3.43M - - - -
Pretax Income 83.31M 149.01M 229.67M 397.57M 526.27M
Income Tax (211.85M) 51.98M 54.35M 142.74M 273.37M
Income Tax - Current Domestic (7.74M) 5.01M (904,000) (2.09M) 141.05M
Income Tax - Current Foreign 4.6M 9.73M 13.19M 73.29M 34.98M
Income Tax - Deferred Domestic (207.6M) 40.57M 45.46M 114.81M 92.04M
Income Tax - Deferred Foreign (1.11M) (3.33M) (3.4M) (43.26M) 5.31M
Income Tax Credits 0 0 0 - 0
Equity in Affiliates 0 0 0 0 0
Other After Tax Income (Expense) 0 0 0 0 0
Consolidated Net Income 295.17M 97.03M 175.32M 254.82M 252.9M
Minority Interest Expense 0 0 0 0 0
Net Income 295.17M 97.03M 175.32M 254.82M 252.9M
Extraordinaries & Discontinued Operations 0 0 0 0 0
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg 0 0 0 0 0
Discontinued Operations 0 0 0 0 0
Net Income After Extraordinaries 295.17M 97.03M 175.32M 254.82M 252.9M
Preferred Dividends 0 0 0 0 0
Net Income Available to Common 295.17M 97.03M 175.32M 254.82M 252.9M
EPS (Basic) 1.73 0.55 0.96 1.34 1.29
Basic Shares Outstanding 170.65M 178.54M 183.22M 190.46M 195.53M
EPS (Diluted) 1.63 0.52 0.91 1.28 1.27
Diluted Shares Outstanding 181.16M 186.07M 191.81M 198.5M 199.71M
EBITDA 96.17M 157.65M 268.49M 411.09M 563.69M
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
(0)
(0)